Patents by Inventor Matthew R. Clutter

Matthew R. Clutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-arylindazoles as selective MEK4 inhibitors
    Patent number: 11370770
    Abstract: Disclosed are indazole compounds and derivatives thereof for use as modulators of the activity of mitogen-activated protein kinase 4 (MEK4). The disclosed compounds include 3-Arylindazoles which may be formulated in pharmaceutical composition for treating cell proliferative diseases and disorders associated with MEK4 activity, including cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: June 28, 2022
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Karl A. Scheidt, Gary E. Schiltz, Matthew R. Clutter, Ada J. Kwong
  • 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS
    Publication number: 20200399241
    Abstract: Disclosed are indazole compounds and derivatives thereof for use as modulators of the activity of mitogen-activated protein kinase 4 (MEK4). The disclosed compounds include 3-Arylindazoles which may be formulated in pharmaceutical composition for treating cell proliferative diseases and disorders associated with MEK4 activity, including cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 24, 2020
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Karl A. Scheidt, Gary E. Schiltz, Matthew R. Clutter, Ada J. Kwong
  • Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
    Patent number: 10851082
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: December 1, 2020
    Assignee: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias
  • SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2)
    Publication number: 20180244654
    Abstract: Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Applicant: Northwestern University
    Inventors: Gary E. Schiltz, Javier Izquierdo-Ferrer, Purav Vagadia, Matthew R. Clutter, Rama K. Mishra, Leonidas C. Platanias